QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 micron-galecto-and-xenetic-lead-this-weeks-benzinga-stock-ranking-surges

Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companies that stood out this week.

 xenetic-biosciences-prices-offering-of-735k-common-shares-at-612shr-for-gross-proceeds-of-45m

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on ad...

 4-stocks-in-the-same-sector-just-made-a-huge-leap-in-momentum-rankings

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam a...

 xenetic-biosciences-q2-eps-045-beats-065-estimate-sales-589897k-miss-720000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $...

 xenetic-biosciences-announces-first-patient-dosing-in-exploratory-clinical-study-of-systemic-dnase-i-in-combination-with-folfirinox-for-advanced-or-metastatic-pancreatic-cancer

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, P...

 xenetic-biosciences-q1-eps-059-beats-072-estimate-sales-59326k-miss-67000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $...

 hc-wainwright--co-reiterates-neutral-on-xenetic-biosciencesto-neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

 hc-wainwright--co-reiterates-neutral-on-xenetic-biosciencesto-neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

 xenetic-biosciences-q4-eps-068-misses-020-estimate-sales-64882k-beat-23000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of...

 xenetic-biosciences-net-loss-for-the-year-ended-december-31-2024-was-4m-ended-the-year-with-62m-of-cash

Summary of Financial Results for Fiscal Year 2024Net loss for the year ended December 31, 2024 was approximately $4.0 million. ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION